Overview

• Lilly agreed to pay $1.3 billion for Cambridge-based Verve at a 113% premium to its 30-day volume-weighted average trading price.
• The acquisition remains subject to approval and is expected to complete in the third quarter of 2025.
• Verve has dosed its first patient with a CRISPR base-editing treatment designed to permanently deactivate the PCSK9 gene and lower LDL cholesterol.
• Verve’s shares surged roughly 80% on June 17 following the deal announcement and news of its first patient dosing.
• The deal advances Lilly’s diversification into cardiovascular genetic medicine while its current valuation sits below its three-year average P/E ratio.